A pegilált interferon biztonságossága hepatitis C-vírus által indukált májcirrhosisos betegeinkben

Translated title of the contribution: Safety of pegylated interferon in patients with hepatitis C virus induced cirrhosis

Research output: Contribution to journalArticle

Abstract

Objectives: The authors described their experience with the therapy with pegylated interferon and its safety in patients with hepatitis C virus (HCV) induced liver cirrhosis treated at First Department of Medicine, Medical School, University of Pécs and at Tawam Hospital, Al Ain, United Arab Emirates. Patients and methods: Twentyfour (12 male, 12 female, average: 55.66 ± 7. 02 years) anti-HCV and/or HCV-RNA PCR positive cirrhotic patients were examined. Liver cirrhosis was diagnosed by abdominal ultrasound and/or histological examination of liver biopsy. Results: Different genotypes of HCV were detected: genotype 1 in 7 cases, genotype 2 in 1 person, genotype 3 in 3 cases. Genotype 4 was detected in 10 patients, all of them were treated out of Hungary. Thirteen of 24 patients were not treated earlier, 6 persons were non-responders to previous interferon monotherapy, pegylated interferon was administered to 5 patients because of relapse. Biochemical parameters showed improvement in 16 cases (16/24, 66.66%), but did not in 5 patients. Until now, virological response was achieved in 13 patients (13/24, 54.16%), while three patients remained HCV-PCR positive. Temporary dose reduction was needed in 13/24 cases (54.16%). Withdrawal of therapy became necessary in only 2 patients due to severe neutropenia, thrombocytopenia and/or signs of decompensation. Conclusions: Pegylated interferon treatment is well tolerated by patients with compensated liver cirrhosis (Child-Pough stage A). Frequent side-effects (half of all cases) were usually mild or moderate requiring discontinuation only in 2 of 24 patients. The incidence of neutropenia and thrombocytopenia emphasizes the need of frequent blood cell count tests and patients follow up.

Original languageHungarian
Pages (from-to)2431-2434
Number of pages4
JournalOrvosi Hetilap
Volume146
Issue number48
Publication statusPublished - 2005

Fingerprint

Hepacivirus
Interferons
Fibrosis
Safety
Genotype
Liver Cirrhosis
Neutropenia
Thrombocytopenia
United Arab Emirates
Polymerase Chain Reaction
Blood Cell Count
Hungary
Patient Safety
Medical Schools
Therapeutics
Medicine
RNA
Biopsy
Recurrence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{efbcc3086ba64d4583226d241fe9644f,
title = "A pegil{\'a}lt interferon biztons{\'a}goss{\'a}ga hepatitis C-v{\'i}rus {\'a}ltal induk{\'a}lt m{\'a}jcirrhosisos betegeinkben",
abstract = "Objectives: The authors described their experience with the therapy with pegylated interferon and its safety in patients with hepatitis C virus (HCV) induced liver cirrhosis treated at First Department of Medicine, Medical School, University of P{\'e}cs and at Tawam Hospital, Al Ain, United Arab Emirates. Patients and methods: Twentyfour (12 male, 12 female, average: 55.66 ± 7. 02 years) anti-HCV and/or HCV-RNA PCR positive cirrhotic patients were examined. Liver cirrhosis was diagnosed by abdominal ultrasound and/or histological examination of liver biopsy. Results: Different genotypes of HCV were detected: genotype 1 in 7 cases, genotype 2 in 1 person, genotype 3 in 3 cases. Genotype 4 was detected in 10 patients, all of them were treated out of Hungary. Thirteen of 24 patients were not treated earlier, 6 persons were non-responders to previous interferon monotherapy, pegylated interferon was administered to 5 patients because of relapse. Biochemical parameters showed improvement in 16 cases (16/24, 66.66{\%}), but did not in 5 patients. Until now, virological response was achieved in 13 patients (13/24, 54.16{\%}), while three patients remained HCV-PCR positive. Temporary dose reduction was needed in 13/24 cases (54.16{\%}). Withdrawal of therapy became necessary in only 2 patients due to severe neutropenia, thrombocytopenia and/or signs of decompensation. Conclusions: Pegylated interferon treatment is well tolerated by patients with compensated liver cirrhosis (Child-Pough stage A). Frequent side-effects (half of all cases) were usually mild or moderate requiring discontinuation only in 2 of 24 patients. The incidence of neutropenia and thrombocytopenia emphasizes the need of frequent blood cell count tests and patients follow up.",
keywords = "Cirrhosis, Hepatitis C virus, Pegylated interferon, Safety",
author = "B. Gasztonyi and G. P{\'a}r and A. P{\'a}r and B. Hunyady",
year = "2005",
language = "Hungarian",
volume = "146",
pages = "2431--2434",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "48",

}

TY - JOUR

T1 - A pegilált interferon biztonságossága hepatitis C-vírus által indukált májcirrhosisos betegeinkben

AU - Gasztonyi, B.

AU - Pár, G.

AU - Pár, A.

AU - Hunyady, B.

PY - 2005

Y1 - 2005

N2 - Objectives: The authors described their experience with the therapy with pegylated interferon and its safety in patients with hepatitis C virus (HCV) induced liver cirrhosis treated at First Department of Medicine, Medical School, University of Pécs and at Tawam Hospital, Al Ain, United Arab Emirates. Patients and methods: Twentyfour (12 male, 12 female, average: 55.66 ± 7. 02 years) anti-HCV and/or HCV-RNA PCR positive cirrhotic patients were examined. Liver cirrhosis was diagnosed by abdominal ultrasound and/or histological examination of liver biopsy. Results: Different genotypes of HCV were detected: genotype 1 in 7 cases, genotype 2 in 1 person, genotype 3 in 3 cases. Genotype 4 was detected in 10 patients, all of them were treated out of Hungary. Thirteen of 24 patients were not treated earlier, 6 persons were non-responders to previous interferon monotherapy, pegylated interferon was administered to 5 patients because of relapse. Biochemical parameters showed improvement in 16 cases (16/24, 66.66%), but did not in 5 patients. Until now, virological response was achieved in 13 patients (13/24, 54.16%), while three patients remained HCV-PCR positive. Temporary dose reduction was needed in 13/24 cases (54.16%). Withdrawal of therapy became necessary in only 2 patients due to severe neutropenia, thrombocytopenia and/or signs of decompensation. Conclusions: Pegylated interferon treatment is well tolerated by patients with compensated liver cirrhosis (Child-Pough stage A). Frequent side-effects (half of all cases) were usually mild or moderate requiring discontinuation only in 2 of 24 patients. The incidence of neutropenia and thrombocytopenia emphasizes the need of frequent blood cell count tests and patients follow up.

AB - Objectives: The authors described their experience with the therapy with pegylated interferon and its safety in patients with hepatitis C virus (HCV) induced liver cirrhosis treated at First Department of Medicine, Medical School, University of Pécs and at Tawam Hospital, Al Ain, United Arab Emirates. Patients and methods: Twentyfour (12 male, 12 female, average: 55.66 ± 7. 02 years) anti-HCV and/or HCV-RNA PCR positive cirrhotic patients were examined. Liver cirrhosis was diagnosed by abdominal ultrasound and/or histological examination of liver biopsy. Results: Different genotypes of HCV were detected: genotype 1 in 7 cases, genotype 2 in 1 person, genotype 3 in 3 cases. Genotype 4 was detected in 10 patients, all of them were treated out of Hungary. Thirteen of 24 patients were not treated earlier, 6 persons were non-responders to previous interferon monotherapy, pegylated interferon was administered to 5 patients because of relapse. Biochemical parameters showed improvement in 16 cases (16/24, 66.66%), but did not in 5 patients. Until now, virological response was achieved in 13 patients (13/24, 54.16%), while three patients remained HCV-PCR positive. Temporary dose reduction was needed in 13/24 cases (54.16%). Withdrawal of therapy became necessary in only 2 patients due to severe neutropenia, thrombocytopenia and/or signs of decompensation. Conclusions: Pegylated interferon treatment is well tolerated by patients with compensated liver cirrhosis (Child-Pough stage A). Frequent side-effects (half of all cases) were usually mild or moderate requiring discontinuation only in 2 of 24 patients. The incidence of neutropenia and thrombocytopenia emphasizes the need of frequent blood cell count tests and patients follow up.

KW - Cirrhosis

KW - Hepatitis C virus

KW - Pegylated interferon

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=33644852789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644852789&partnerID=8YFLogxK

M3 - Article

C2 - 16408382

AN - SCOPUS:33644852789

VL - 146

SP - 2431

EP - 2434

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 48

ER -